Payer Policy Changes for Billing Teams

Policy	Payer	Type	Specialty	Date
Tumor Antigen by Immunoassay - CA 125 — NCD 130 \| CMS Coverage Update	CMS	Modified	Oncology	Mar 12, 2026
Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of Wounds — NCD 131 \| CMS Coverage Update	CMS	Modified	DME & Home Health	Mar 12, 2026
L-Dopa — NCD 132 \| CMS Coverage Update	CMS	Modified	Neurology & Neurosurgery	Mar 12, 2026
Insulin Syringe — NCD 133 \| CMS Coverage Update	CMS	Modified	Endocrinology	Mar 12, 2026
Tumor Antigen by Immunoassay - CA 15-3/CA 27.29 — NCD 134 \| CMS Coverage Update	CMS	Modified	Oncology	Mar 12, 2026
Vitamin B12 Injections to Strengthen Tendons, Ligaments, etc., of the Foot — NCD 135 \| CMS Coverage Update	CMS	Modified	Podiatry	Mar 12, 2026
Hydrophilic Contact Lens For Corneal Bandage — NCD 136 \| CMS Coverage Update	CMS	Modified	Ophthalmology	Mar 12, 2026
Laetrile and Related Substances — NCD 137 \| CMS Coverage Update	CMS	Modified	Oncology	Mar 12, 2026
Autogenous Epidural Blood Graft — NCD 138 \| CMS Coverage Update	CMS	Modified	Pain Management	Mar 12, 2026
Porcine Skin and Gradient Pressure Dressings — NCD 139 \| CMS Coverage Update	CMS	Modified	Dermatology	Mar 12, 2026
Plastic Surgery to Correct \"Moon Face\" — NCD 14 \| CMS Coverage Update"Moon Face\\" — \| CMS Coverage Update — NCD 14 \| CMS Coverage Update	CMS	Modified	General / Multi-Specialty	Mar 12, 2026
Physician's Office within an Institution Coverage of Services and Supplies Incident to a Physician's Services — NCD 140 \| CMS Coverage Update	CMS	Modified	General / Multi-Specialty	Mar 12, 2026
Certain Drugs Distributed by the National Cancer Institute — NCD 141 \| CMS Coverage Update	CMS	Modified	Oncology, Pharmacy	Mar 12, 2026
Tumor Antigen by Immunoassay - CA 19-9 — NCD 142 \| CMS Coverage Update	CMS	Modified	Oncology	Mar 12, 2026
Transfer Factor for Treatment of Multiple Sclerosis — NCD 143 \| CMS Coverage Update	CMS	Modified	Neurology & Neurosurgery	Mar 12, 2026
Granulocyte Transfusions — NCD 144 \| CMS Coverage Update	CMS	Modified	Hematology	Mar 12, 2026
Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain — NCD 145 \| CMS Coverage Update	CMS	Modified	Pain Management	Mar 12, 2026
Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis — NCD 146 \| CMS Coverage Update	CMS	Modified	Cardiology	Mar 12, 2026
Scalp Hypothermia During Chemotherapy to Prevent Hair Loss — NCD 147 \| CMS Coverage Update	CMS	Modified	Oncology	Mar 12, 2026
Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) — NCD 148 \| CMS Coverage Update	CMS	Modified	Hematology	Mar 12, 2026
Dimethyl Sulfoxide (DMSO) — NCD 149 \| CMS Coverage Update	CMS	Modified	Urology & Nephrology	Mar 12, 2026
Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing Agents — NCD 15 \| CMS Coverage Update	CMS	Modified	Pain Management	Mar 12, 2026
Anti-Inhibitor Coagulant Complex (AICC) — NCD 150 \| CMS Coverage Update	CMS	Modified	Hematology	Mar 12, 2026
Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) — NCD 151 \| CMS Coverage Update	CMS	Modified	Gastroenterology	Mar 12, 2026
Prostate Specific Antigen — NCD 152 \| CMS Coverage Update	CMS	Modified	Urology & Nephrology	Mar 12, 2026

Payer policy changesfor billing and compliance teams.

One missed policy change can cost thousands in denied claims.

Payer policy changes
for billing and compliance teams.